Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jean-Jacques Body

Showing results (71-80 of 133) with videos related to

Pageof 14
Sort By:
Nutrients|August 10, 2024
When and How to Evaluate Vitamin D Status? A Viewpoint from the Belgian Bone ClubBruno Lapauw, Michaël R Laurent, Serge Rozenberg, et al.
Archives of Osteoporosis|June 27, 2023
Risk factors predicting the 'time to first fracture' and its association with imminent fractures: a substudy of the FRISBEE cohortJeroen M K de Filette, Alexia Charles, Amélie Bellanger, et al.
Archives of Osteoporosis|April 24, 2020
Underevaluation of fractures by self-report: an analysis from the FRISBEE cohortFelicia Baleanu, Michel Moreau, Virginie Kinnard, et al.
Current Medical Research and Opinion|December 15, 2018
Bone-targeted agent treatment patterns and the impact of bone metastases on patients with advanced breast cancer in the United StatesDavid Henry, Roger von Moos, Jean-Jacques Body, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|September 3, 2010
European French-speaking study from the GEMO group on bone metastases management: a special focus on external beam radiotherapy practice surveyNicolas Magné, Cyrus Chargari, René Olivier Mirimanoff, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 21, 2006
A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancerJean-Jacques Body, Thierry Facon, Robert E Coleman, et al.
Frontiers in Endocrinology|June 27, 2022
Prevention and Treatment of Glucocorticoid-Induced Osteoporosis in Adults: Consensus Recommendations From the Belgian Bone ClubMichaël R Laurent, Stefan Goemaere, Charlotte Verroken, et al.
BMC Health Services Research|July 5, 2018
Physicians' preferences for bone metastases treatments in France, Germany and the United KingdomYi Qian, Jorge Arellano, Francesca Gatta, et al.
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|January 29, 2013
Health state utilities for skeletal-related events secondary to bone metastasesLouis S Matza, Karen Chung, Kate Van Brunt, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 25, 2009
Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonatesKarim Fizazi, Allan Lipton, Xavier Mariette, et al.
Pageof 14

Showing results (71-80 of 133) with videos related to

Sort By:
Pageof 14
Nutrients|August 10, 2024
When and How to Evaluate Vitamin D Status? A Viewpoint from the Belgian Bone ClubBruno Lapauw, Michaël R Laurent, Serge Rozenberg, et al.
Archives of Osteoporosis|June 27, 2023
Risk factors predicting the 'time to first fracture' and its association with imminent fractures: a substudy of the FRISBEE cohortJeroen M K de Filette, Alexia Charles, Amélie Bellanger, et al.
Archives of Osteoporosis|April 24, 2020
Underevaluation of fractures by self-report: an analysis from the FRISBEE cohortFelicia Baleanu, Michel Moreau, Virginie Kinnard, et al.
Current Medical Research and Opinion|December 15, 2018
Bone-targeted agent treatment patterns and the impact of bone metastases on patients with advanced breast cancer in the United StatesDavid Henry, Roger von Moos, Jean-Jacques Body, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|September 3, 2010
European French-speaking study from the GEMO group on bone metastases management: a special focus on external beam radiotherapy practice surveyNicolas Magné, Cyrus Chargari, René Olivier Mirimanoff, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 21, 2006
A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancerJean-Jacques Body, Thierry Facon, Robert E Coleman, et al.
Frontiers in Endocrinology|June 27, 2022
Prevention and Treatment of Glucocorticoid-Induced Osteoporosis in Adults: Consensus Recommendations From the Belgian Bone ClubMichaël R Laurent, Stefan Goemaere, Charlotte Verroken, et al.
BMC Health Services Research|July 5, 2018
Physicians' preferences for bone metastases treatments in France, Germany and the United KingdomYi Qian, Jorge Arellano, Francesca Gatta, et al.
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|January 29, 2013
Health state utilities for skeletal-related events secondary to bone metastasesLouis S Matza, Karen Chung, Kate Van Brunt, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 25, 2009
Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonatesKarim Fizazi, Allan Lipton, Xavier Mariette, et al.
Pageof 14